185 related articles for article (PubMed ID: 17603216)
1. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Inoue S; Ohtani H; Tsujimoto M; Hori S; Sawada Y
Drug Metab Pharmacokinet; 2007 Jun; 22(3):162-8. PubMed ID: 17603216
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
4. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Lee HW; Seong SJ; Kang WY; Ohk B; Gwon MR; Kim BK; Cho S; Cho K; Sung YK; Yoon YR; Kim JG
Drug Des Devel Ther; 2019; 13():3127-3136. PubMed ID: 31564829
[TBL] [Abstract][Full Text] [Related]
6. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Tanaka J; Oshiro R; Tatsuta M; Masutani S; Fukunaga M; Nakayama T; Takemoto H; Kondo M; Kamigaki S; Kawasaki T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1748-51. PubMed ID: 16315929
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Liu HY; Ding L; Yu Y; Chu Y; Zhu H
Yao Xue Xue Bao; 2012 Oct; 47(10):1363-9. PubMed ID: 23289150
[TBL] [Abstract][Full Text] [Related]
8. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Tanaka T; Fujita S; Tanaka N; Ooka M; Okajima S; Tanaka N
Gan To Kagaku Ryoho; 2005 Jun; 32(6):841-5. PubMed ID: 15984528
[TBL] [Abstract][Full Text] [Related]
9. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
11. Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats.
Kobuchi S; Ito Y; Takamatsu D; Sakaeda T
Eur J Pharm Sci; 2018 Oct; 123():452-458. PubMed ID: 30077713
[TBL] [Abstract][Full Text] [Related]
12. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
Kim TH; Shin S; Shin JC; Bulitta JB; Weon KY; Yoo SD; Park GY; Jeong SW; Kwon DR; Min BS; Woo MH; Shin BS
Molecules; 2017 Sep; 22(9):. PubMed ID: 28880240
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
14. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
[TBL] [Abstract][Full Text] [Related]
15. [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
Takahashi N; Nitta A; Saitou T; Mori Y; Kunii Y; Kikuchi K
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2319-23. PubMed ID: 3136701
[TBL] [Abstract][Full Text] [Related]
16. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Saif MW; Rosen LS; Saito K; Zergebel C; Ravage-Mass L; Mendelson DS
Anticancer Res; 2011 Feb; 31(2):625-32. PubMed ID: 21378348
[TBL] [Abstract][Full Text] [Related]
17. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
18. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Damle B; Ravandi F; Kaul S; Sonnichsen D; Ferreira I; Brooks D; Stewart D; Alberts D; Pazdur R
Clin Cancer Res; 2001 Mar; 7(3):517-23. PubMed ID: 11297242
[TBL] [Abstract][Full Text] [Related]
19. [Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
Tomita T; Tajima T; Ishibashi M; Tagaya N; Aoki H; Itoh S; Kadowaki A; Kogure H; Tajima Y
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3755-62. PubMed ID: 2512859
[TBL] [Abstract][Full Text] [Related]
20. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
